Carrick Therapeutics

What Carrick Therapeutics does

Carrick Therapeutics is a clinical-stage biopharmaceutical company developing a focused portfolio of first-in-class cyclin-dependent kinase (CDK) inhibitors for the treatment of aggressive and treatment-resistant solid tumors. The company's lead asset, samuraciclib (CT7001), is an oral CDK7 inhibitor that regulates transcription of cancer-causing genes and suppresses resistance to anti-hormone therapy; it is currently being evaluated in Phase 2 clinical trials in combination with fulvestrant, elacestrant, and vepdegestrant in hormone receptor positive (HR+), HER2-negative advanced breast cancer, with exploratory programs in prostate, pancreatic, ovarian, colorectal, and triple-negative breast cancer. The second core asset, CT7439, is a first-in-class CDK12/13 inhibitor with a dual Cyclin-K glue-degrader mechanism that inhibits DNA damage response genes; it entered Phase 1 clinical development in September 2024 in ovarian, breast, and Ewing's Sarcoma.

The company's pipeline is differentiated by novel molecular architecture and FDA Fast Track designations in HR+ breast cancer and TNBC. Carrick employs biomarker-driven patient selection using ctDNA liquid biopsy to identify responders based on TP53 and ESR1 mutation status, with positive Phase 2 SUMIT-BC data announced in December 2025 showing median PFS of 14.5 months and ORR of 55% in TP53 wild-type patients.

The company is pre-revenue with no approved products and generates no product sales. Its business model relies on clinical development partnerships with large pharmaceutical companies — Pfizer, Roche, Menarini Group, and Arvinas — each of which supplies its own anti-cancer agent in combination trials while Carrick retains full economic ownership of its pipeline assets. Future revenue is expected through licensing agreements, co-development economics, and eventual commercialization, either independently or through partners. The company is headquartered in Boston, Massachusetts (relocated from Dublin, Ireland in June 2024) and maintains research and development operations in Oxford, United Kingdom.

Name

Carrick Therapeutics

Legal name

Carrick Therapeutics Limited

Website

https://carricktherapeutics.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Carrick Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class CDK7 (samuraciclib) and CDK12/13 (CT7439) inhibitors for advanced solid tumors, partnered with Pfizer, Roche, Menarini, and Arvinas for combination oncology trials.

Ownership category

akta.pro rank

Product category

Clinical-Stage Oncology Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Oncology therapeutics
• CDK inhibitors
• Clinical-stage biopharmaceutical
• Cancer drug development
• Breast cancer therapy

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical Development and Licensing: Carrick Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative oncology therapies. The company has not yet generated revenue from product sales. Revenue generation is expected through future product licensing agreements, co-development partnerships, and eventual commercialization of approved therapies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Carrick Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class small-molecule cyclin-dependent kinase (CDK) inhibitors for the treatment of aggressive and resistant cancers. Its lead asset samuraciclib (CT7001) is an oral CDK7 inhibitor in Phase 2 clinical trials for HR+ HER2- advanced breast cancer and other solid tumors, while CT7439 is a first-in-class CDK12/13 inhibitor and Cyclin-K glue-degrader in Phase 1 development. The company partners with Pfizer, Roche, Menarini Group, and Arvinas to evaluate its assets in combination with endocrine therapies and DDR-targeting agents.

Product overview

Carrick Therapeutics is a clinical-stage biopharmaceutical company developing a focused portfolio of differentiated cancer therapies targeting cyclin-dependent kinases. The company's lead product is samuraciclib (CT7001), an oral first-in-class CDK7 inhibitor currently in multiple Phase 2 clinical trials for HR+ breast cancer and other solid tumors. The second product, CT7439, is a first-in-class CDK12/13 inhibitor and Cyclin-K glue-degrader in Phase 1 clinical development for ovarian, breast and Ewing's Sarcoma. Both products are being evaluated in combination with existing endocrine therapies (SERDs) to address resistance to CDK4/6 inhibitors in advanced breast cancer.

Differentiator

Problem solved

Functional benefit

Products and services

• Samuraciclib (CT7001) An oral, first-in-class cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of hormone receptor positive (HR+) HER2- advanced breast cancer, triple negative breast cancer, prostate, pancreatic, ovarian, and colorectal cancers. CDK7 regulates transcription of cancer-causing genes, promotes uncontrolled cell cycle progression, and promotes resistance to anti-hormone therapy. The most advanced CDK7 inhibitor in clinical development, with FDA Fast Track designations.
• CT7439 A first-in-class oral inhibitor of CDK12/13 and Cyclin-K glue-degrader for the treatment of advanced solid tumors including ovarian, breast, and Ewing's Sarcoma. CDK12/13 regulates gene transcription through RNA Polymerase II activation and DNA damage response genes. The dual modality significantly increases potency and leads to inhibition of DNA repair at the transcriptional level, with potential synergy with PARP inhibitors.

Quantifiable outcome

• Median PFS of 14.5 months in TP53 wild-type patients (samuraciclib + fulvestrant vs 6.8 months fulvestrant alone)
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Four partnerships are on record, tiered supporting and core.

• Pfizer IgnitesupportingStrategic or Co-development Partner · 15 December 2023Pfizer Ignite provides end-to-end service for biotech companies with high potential science, leveraging R&D capabilities, scale and expertise. Supports the Phase 2b SUMIT-BC clinical trial evaluating samuraciclib with fulvestrant.
• Arvinas and PfizercoreStrategic or Co-development Partner · 6 July 2023Clinical trial collaboration and supply agreement for Phase 1b/2 clinical trial evaluating samuraciclib (CDK7 inhibitor) in combination with vepdegestrant (ARV-471), Arvinas' oral PROTAC estrogen receptor protein degrader, in ER+, HER2- metastatic breast cancer patients. Arvinas is the regulatory sponsor in the U.S.; Pfizer is acting sponsor for U.S. study and regulatory/acting sponsor outside U.S. Three parties collaborate through a Joint Development Committee.
• The Menarini GroupcoreStrategic or Co-development Partner · 19 December 2022Clinical trial collaboration and supply agreement for Phase 2 clinical trial evaluating samuraciclib in combination with elacestrant (Menarini's oral SERD) in CDK4/6i resistant HR+, HER2- metastatic breast cancer. Menarini and Carrick jointly sponsor the clinical trial.
• RochecoreStrategic or Co-development Partner · 2 August 2021Clinical collaboration utilizing Roche's MORPHEUS Phase 1b/2 platform to evaluate samuraciclib in combination with Roche's giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer. Each company supplies its respective anti-cancer agent.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Arvinas: Arvinas is a clinical-stage oncology company pioneering PROTAC targeted protein degraders (e.g., vepdegestrant/ARV-471) and is an active clinical collaborator with Carrick — directly comparable as a partner and as a peer in targeted oncology with novel degradation mechanisms.
• Repare Therapeutics: Repare Therapeutics is a clinical-stage precision oncology company focused on synthetic lethality and DDR-targeted therapies, comparable to Carrick's biomarker-driven oncology strategy and CDK12/13-related DNA damage response positioning.
• Theseus Pharmaceuticals: Theseus Pharmaceuticals was a clinical-stage oncology company developing kinase inhibitors targeting resistance mutations, comparable to Carrick's kinase-inhibitor oncology strategy and biomarker-driven positioning.
• Kymera Therapeutics: Kymera Therapeutics is a clinical-stage company developing targeted protein degraders using distinct chemistries, comparable to Carrick's CT7439 on the protein-degradation modality axis and to broader clinical-stage targeted oncology peers.
• Blueprint Medicines: Blueprint Medicines is a clinical-to-commercial stage precision oncology company developing kinase-targeted therapies, including CDK4/6 and other CDK-related programs, comparable to Carrick's kinase-inhibitor oncology focus and biomarker-driven approach.
• Syros Pharmaceuticals: Syros Pharmaceuticals is a clinical-stage oncology company developing CDK7 inhibitors (e.g., SY-5609) and other targeted therapies, making it the most directly comparable peer to Carrick's samuraciclib program in the CDK7 inhibitor space.
• Nuvalent: Nuvalent is a clinical-stage precision oncology company developing kinase inhibitors with a focus on resistance mutations and selectivity, comparable to Carrick as a similarly-sized clinical-stage targeted oncology biotech.
• Monte Rosa Therapeutics: Monte Rosa Therapeutics is a clinical-stage company developing molecular glue degraders — directly analogous to Carrick's CT7439 Cyclin-K glue-degrader mechanism — for oncology and other diseases, making it a key peer on the degrader modality axis.
• Foghorn Therapeutics: Foghorn Therapeutics is a clinical-stage oncology company developing chromatin biology-based therapies including programs targeting the CDK pathway and transcription regulation, comparable to Carrick's CDK-targeted transcription regulation approach.

Broad incumbents

• Incyte Corporation: Incyte is a larger established oncology biopharma with CDK4/6 inhibitor (Jakavi/partner programs) and a broad kinase-inhibitor portfolio including multiple programs in HR+ breast cancer — directly competitive as a broad incumbent in the indication Carrick targets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/10939807

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carrick Therapeutics